Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 20/2/2021
SIETES contiene 93212 citas

 
 
<< anterior 21 a 40 de 211 siguiente >>
Presentar resultados
Seleccionar todas
21. Cita con resumen
Bennett CL, Nebeker JR, Yarnold PR, Tigue CC, Dorr DA, McKoy JM, Edwards BJ, Hurdle JF, West DP, Lau DT, Angelotta C, Weitzman SA, Belknap SM, Djulbegovic B, Tallman MS, Kuzel TM, Benson AB, Evens A, Trifilio SM, Courtney DM, Raisch DW. Evaluation of serious adverse drug reactions. A proactive pharmacovigilance program (RADAR) vs safety activities conducted by the Food and Drug Administration and pharmaceutical manufacturers. Arch Intern Med 2007;167:1041-9. [Ref.ID 80227]
22.Tiene citas relacionadas Cita con resumen
Andersohn F, Konzen C, Garbe E. Systematic review: agranulocytosis induced by nonchemotherapy drugs. Ann Intern Med 2007;146:657-65. [Ref.ID 80061]
23.
Eshaghian S, Amin S, Shah PK, Diamond GA. Role of clopidogrel in managing atherothrombotic cardiovascular disease. Ann Intern Med 2007;146:434-41. [Ref.ID 79711]
24. Cita con resumen
Tavassoli N, Duchayne E, Sadaba B, Desboeuf K, Sommet A, Lapeyre-Mestre M, Muoz MJ, Sie P, Honorato J, Montastruc J-L, Bagheri H. Detection and incidence of drug-induced agranulocytosis in hospital: a prospective analysis from laboratory signals. Eur J Clin Pharmacol 2007;63:221-8. [Ref.ID 79523]
25. Cita con resumen
Motola D, Vargiu A, Leone R, Cocci A, Salvo F, Ros B, Meneghelli I, Venegoni M, Cutroneo PM, Vaccheri A, Velo G, Montanaro N. Hepatic adverse drug reactions: a case/non-case study in Italy. Eur J Clin Pharmacol 2007;63:73-9. [Ref.ID 79050]
26.Enlace a cita original Cita con resumen
Lanas A, García-Rodríguez LA, Arroyo MT, Gomollón F, Feu F, González-Pérez A, Zapata E, Bastida G, Rodrigo L, Santolaria S, Güell M, Martín de Argila C, Quintero E, Borda F, Piqué JM, on behalf of the Investigators of the Asociación Española de Gastroenterología (AEG). Risk of upper gastrointestinal ulcer bleeding associated with selective COX-2 inhibitors, traditional non-aspirin NSAIDs, aspirin, and combinations. Gut 2006;55:1731-8. [Ref.ID 77995]
27. Cita con resumen
Ibáñez L, Vidal X, Vendrell L, Moretti U, Laporte JR, on behalf of the Spanish-Italian Collaborative Group for the Epidemiology of Gastrointestinal Bleeding. Upper gastrointestinal bleeding associated with antiplatelet drugs. Aliment Pharmacol Ther 2006;23:235-42. [Ref.ID 76599]
28. Cita con resumen
Ibáñez L, Vidal X, Ballarín E, Laporte JR. Population-based drug-induced agranulocytosis. Arch Intern Med 2005;165:869-74. [Ref.ID 73758]
30. Cita con resumen
Sanderson S, Baglin T, Kinmonth A-L. Narrative review: aspirin resistance and its clinical implications. Ann Intern Med 2005;142:370-80. [Ref.ID 73355]
31. Cita con resumen
Garattini S, Bertele V. Risk: benefit assessment of old medicines. Br J Clin Pharmacol 2004;58:581-6. [Ref.ID 72226]
32.Tiene citas relacionadas
Toole JF, Sane DC, Bettermann K. Stroke prevention. Optimizing the response to a commonthreat. JAMA 2004;292:1885-7. [Ref.ID 71629]
33.Tiene citas relacionadas
Schulman SP. Antiplatelet therapy in non-ST-segment elevation acute coronary syndromes. JAMA 2004;292:1875-82. [Ref.ID 71627]
35. Cita con resumen
Ibáñez L, Laporte JR, Leone R, Vendrell L, Vidal X. Upper gastrointestinal bleeding and antiplatelet drugs. Pharmacoepidemiol Drug Saf 2004;13:S142-3. [Ref.ID 71459]
36. Cita con resumen
Jacoby D, Mohler III ER. Drug treatment of intermittent claudication. Drugs 2004;64:1657-70. [Ref.ID 70945]
37. Cita con resumen
Anónimo. Interacciones del acenocumarol con importancia clínica. Boletín Terapéutico Andaluz 2004;20:1-4. [Ref.ID 70099]
39.
Anónimo. Évaluation du clopidogrel (suite). Prescrire 2003;23:542. [Ref.ID 66700]
40.Tiene citas relacionadas
Sacco RL. Preventing stroke among blacks. The challenges continues. JAMA 2003;289:3005-7. [Ref.ID 66547]
Seleccionar todas
 
<< anterior 21 a 40 de 211 siguiente >>